Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Lazertinib Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentAmbetter NevadaPolicy CP.PHAR.695

    Clinical Policy: Lazertinib (Lazcluze)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PHAR.695 alerts

    Get alerted when Policy CP.PHAR.695 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for oral lazertinib (Lazcluze) in commercial, marketplace/ICHRA, and Medicaid lines of business. It applies to adult members with recurrent, advanced, or metastatic non-small cell lung cancer and specifies initial- and continued-therapy requirements.

    Policy Summary
    PayerAmbetter Nevada
    PolicyClinical Policy: Lazertinib (Lazcluze)
    Policy CodePolicy CP.PHAR.695
    Change TypeMaterial clinical and administrative updates
    Effective DateDecember 1, 2024
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming the covered NSCLC diagnosis, oncologist involvement, EGFR mutation status, permitted regimen, and dose requirements.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added Lazcluze monotherapy as an allowed treatment option for first-line therapy and continuation therapy after progression in specified asymptomatic or limited-progressive disease settings.

    The policy added combination Lazcluze and Rybrevant as subsequent therapy following Tagrisso-based therapy.

    The policy added the health insurance marketplace/ICHRA line of business.

    Initial approval duration was revised to 12 months.

    12 monthsApproval duration
    240 mg/dayMaximum daily dose
    2 tablets/day

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum tablets per day
    18 yearsMinimum age
    30 daysMinimum treatment duration
    80 mg and 240 mgTablet strengths

    Coverage Criteria

    Other diagnoses or indications

    Other diagnoses or indications must meet one of the following pathways.

    • Recent label change

      • The drug has undergone a label change within the last 6 months that is not yet reflected in this policy, and the applicable no-coverage criteria policy is used for a drug on the formulary or PDL.Label change within the last 6 months

        Commercial: CP.CPA.190; marketplace/ICHRA: HIM.PA.33; Medicaid: CP.PMN.255.

      • The drug has undergone a label change within the last 6 months that is not yet reflected in this policy, and the applicable non-formulary policy is used for a drug not on the formulary or PDL.Label change within the last 6 months

        Commercial: CP.CPA.190; marketplace/ICHRA: HIM.PA.103; Medicaid: CP.PMN.16.

    • Other use not specifically listed as unauthorized

      • The requested use, including the diagnosis, age, or dosing regimen, is not specifically listed under diagnoses or indications for which coverage is not authorized, and the recent-label-change pathway does not apply.
      • Refer to the applicable off-label use policy.

        Commercial: CP.CPA.09; marketplace/ICHRA: HIM.PA.154; Medicaid: CP.PMN.53.

    Continuation therapy: NSCLC

    Covered for continued therapy when all of the following are met.

    Continued therapy criteria

    • Current therapy status

      • Member is currently receiving the medication through the Centene benefit.
      • Documentation supports that the member is currently receiving Lazcluze for a covered indication and has received it for at least 30 days.>=30 days
    • Response and utilization

      • Member is responding positively to therapy.
      • For a Lazcluze request, the member must use lazertinib when available unless lazertinib is contraindicated or clinically significant adverse effects have been experienced.

    Non-FDA-approved indications that are not addressed in this policy are not authorized unless sufficient documentation of efficacy and safety supports review under the applicable off-label use policy or evidence of coverage documents. Applicable off-label policies vary by line of business.

    Dose and Quantity Coding Limits

    Maximum dose
    Maximum standard daily dose240 mg per day
    Applies toInitial therapy and dose increases for continued therapy
    Alternative dosing pathwayA higher or different dose may be considered when supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with prescriber-submitted evidence
    Maximum tablet quantity
    Maximum standard tablet quantity2 tablets per day
    Applies toInitial therapy and dose increases for continued therapy
    Alternative quantity pathway

    Provider Requirements and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. The provider must submit documentation demonstrating that all applicable approval criteria for Lazcluze have been met, including the covered indication, prescribing requirements, dosing requirements, and any applicable exceptions.

    • Submit evidence supporting every applicable initial- or continued-therapy criterion.
    • The prescribed regimen must be FDA-approved or recommended by NCCN, unless an allowed guideline- or literature-supported off-label exception applies.
    Step Therapy

    Lazertinib Utilization Requirement

    For Lazcluze requests, the member must use lazertinib when available unless it is contraindicated or the member experiences clinically significant adverse effects.

    • Document the applicable contraindication or clinically significant adverse effect when lazertinib is not used.
    • This requirement applies to both initial and continued therapy.

    Background

    Lazertinib (Lazcluze) is a kinase inhibitor used to manage EGFR-mutated non-small cell lung cancer. The FDA-approved indication described in this policy is first-line treatment, in combination with amivantamab (Rybrevant), for adults with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletion or exon 21 L858R substitution mutations detected by an FDA-approved test.

    Definitions

    Lazertinib
    MedicationLazertinib (Lazcluze)
    Drug classKinase inhibitor
    Policy useUsed in the management of EGFR-mutated non-small cell lung cancer
    EGFR
    Full termEpidermal growth factor receptor
    Relevant mutation statusEGFR exon 19 deletions or exon 21 L858R substitution mutations
    Testing requirementMutations are detected by an FDA-approved test

    Initial Therapy

    Continued Therapy

    Step-Therapy Requirement

    StepRequirementPermitted exceptions
    1For Lazcluze requests, the member must use lazertinib when available.The requirement does not apply when lazertinib is contraindicated or the member has experienced clinically significant adverse effects.

    Quantity Limits

    Lazcluze (lazertinib)
    MedicationLazcluze (lazertinib)
    Maximum covered dose240 mg per day
    Standard regimen context240 mg PO QD in combination with amivantamab for NSCLC
    Lazcluze (lazertinib)
    MedicationLazcluze (lazertinib)
    Maximum covered tablet quantity2 tablets per day
    Applies toInitial requests and dose increases for continued therapy
    Policy Summary
    PayerAmbetter Nevada
    PolicyClinical Policy: Lazertinib (Lazcluze)
    Policy CodePolicy CP.PHAR.695
    Change TypeMaterial clinical and administrative updates
    Effective DateDecember 1, 2024
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming the covered NSCLC diagnosis, oncologist involvement, EGFR mutation status, permitted regimen, and dose requirements.
    SourceLink
    On This Page
    Coverage CriteriaDose and Quantity Coding LimitsProvider Requirements and Denial RisksBackgroundDefinitionsInitial TherapyContinued TherapyStep-Therapy RequirementQuantity Limits
  1. Dose increase requirement

    • The new dose does not exceed 240 mg per day and does not exceed 2 tablets per day.<=240 mg/day and <=2 tablets/day
    • The new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.

      The prescribed regimen must be FDA-approved or recommended by NCCN.

  2. A different tablet quantity may be considered when supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with prescriber-submitted evidence
    Documentation Required

    Clinical Documentation Required

    Submit clinical documentation supporting that the member has met all approval criteria. Acceptable supporting information may include office chart notes, laboratory results, and other relevant clinical records.

    • Include sufficient records to establish diagnosis, disease status, treatment history, response to therapy, and the requested regimen.
    • Ensure submitted documentation is current and directly supports the request.
    Documentation Required

    Initial-Therapy Supporting Records

    For initial therapy, submit records establishing the covered NSCLC indication and the member’s eligibility for treatment with Lazcluze.

    • Diagnosis of recurrent, advanced, or metastatic non-small cell lung cancer.
    • Prescription by, or consultation with, an oncologist.
    • Member is age 18 years or older.
    • Tumor is positive for an EGFR exon 19 deletion or exon 21 L858R substitution mutation.
    • Treatment plan identifies an allowed regimen: single-agent Lazcluze as first-line therapy or qualifying continuation therapy, or Lazcluze in combination with Rybrevant as first-line, qualifying continuation, or subsequent therapy following Tagrisso-based therapy.
    Documentation Required

    Evidence for Nonstandard Dosing

    If the requested dose exceeds the standard limit, the prescriber must provide evidence supporting the regimen for the relevant off-label use.

    • Standard dose must not exceed both 240 mg per day and 2 tablets per day.
    • For a dose outside those limits, submit applicable practice guidelines or peer-reviewed literature supporting the dose.
    • The prescribed regimen must be FDA-approved or recommended by NCCN.
    Documentation Required

    Continuation Records

    For continued therapy, document that the member is eligible for continuation and is benefiting from treatment.

    • Member is currently receiving the medication through a Centene benefit, or documentation supports current Lazcluze use for a covered indication for at least 30 days.
    • Document that the member is responding positively to therapy.
    • For a dose increase, document that the new dose does not exceed both 240 mg per day and 2 tablets per day, or provide practice-guideline or peer-reviewed literature supporting the new dose for the relevant off-label use.

    Unsupported block type: denial_risk放?

    Denial Risk

    Initial Approval Denial Risks

    An initial request may be denied when the member does not meet all applicable NSCLC criteria or when the requested regimen does not satisfy the utilization and dosing requirements.

    • The request lacks documentation of recurrent, advanced, or metastatic NSCLC; oncology prescribing or consultation; age 18 years or older; or an EGFR exon 19 deletion or exon 21 L858R mutation.
    • The proposed treatment does not fit an allowed Lazcluze single-agent or Rybrevant combination treatment pathway.
    • The member does not use lazertinib when available and no contraindication or clinically significant adverse effect is documented.
    • The dose exceeds 240 mg per day and 2 tablets per day without supporting guideline or peer-reviewed literature.
    Denial Risk

    Continuation Approval Denial Risks

    A continued-therapy request may be denied when continuation criteria are not documented or the member is not demonstrating benefit from treatment.

    • The member is not receiving the medication through a Centene benefit and there is no documentation of at least 30 days of current Lazcluze use for a covered indication.
    • The member is not responding positively to therapy.
    • The member does not use lazertinib when available and no contraindication or clinically significant adverse effect is documented.
    • A requested dose increase exceeds 240 mg per day and 2 tablets per day without supporting guideline or peer-reviewed literature.
    NSCLC
    Full termNon-small cell lung cancer
    AbbreviationNSCLC
    Covered disease contextLocally advanced or metastatic disease, including disease with specified EGFR mutations
    FDA
    Full termFood and Drug Administration
    Policy referenceAn FDA-approved test is used to detect specified EGFR mutations
    Regimen referenceThe prescribed regimen must be FDA-approved or recommended by NCCN